UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 25, 2014
ARNO THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
000-52153 |
|
52-2286452 |
(Commission File Number) |
|
(IRS Employer |
|
|
Identification No.) |
200 Route 31 North, Suite 104
Flemington, NJ 08822
(Address of principal executive offices
and Zip Code)
(862) 703-7170
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-14(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 | Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On July 25, 2014, Arno Therapeutics, Inc.
(the “Company” or “Arno”) entered into a Separation Agreement (the “Separation Agreement”)
with Glenn R. Mattes, the Company’s former President and Chief Executive Officer and member of its Board of Directors. Pursuant
to the Separation Agreement, Mr. Mattes and Arno mutually agreed that Mr. Mattes’ employment with Arno, as well
as the Employment Agreement between Arno and Mr. Mattes dated April 25, 2011 (the “Employment Agreement”), terminated
on July 18, 2014 (the “Separation Date”). Mr. Mattes also resigned as a director of Arno effective as of the Separation
Date.
In accordance with the terms of the Separation
Agreement, and subject to Mr. Mattes’ non-revocation of a release of claims, Arno will continue to pay to Mr. Mattes his
current annualized base salary for a period of 13 months following the Separation Date, which amounts to an aggregate of $426,508.33.
In addition, the Separation Agreement provides that all vested stock options held by Mr. Mattes as of the Separation Date
will remain exercisable for a period of three years following the Separation Date and such stock options may be exercised on a
cashless (net) exercise basis. Accordingly, as of the Separation Date, Mr. Mattes holds stock options to purchase 432,896 shares
of the Company’s common stock, all of which are exercisable at $2.40 per share. In consideration of the foregoing, the Separation
Agreement provides for Mr. Mattes’ release of claims.
The foregoing description of the material
terms of the Separation Agreement is qualified in its entirety by reference to the full text of the agreement, which is attached
hereto and incorporated by reference herein as Exhibit 10.1.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. |
|
Description |
10.1 |
|
Separation Agreement by and between Arno Therapeutics, Inc. and Glenn R. Mattes dated July 25, 2014. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 31, 2014
|
Arno Therapeutics, Inc. |
|
|
|
|
|
|
By: |
/s/ Lawrence Kenyon |
|
|
|
Lawrence Kenyon |
|
|
|
Chief Operating Officer and Chief |
|
|
|
Financial Officer |
|
EXHIBIT INDEX
Exhibit No. |
|
Description |
10.1 |
|
Separation Agreement by and between Arno Therapeutics, Inc. and Glenn R. Mattes dated July 25, 2014. |
|
|
|
Exhibit 10.1
SEPARATION AGREEMENT
THIS SEPARATION AGREEMENT
(the “Agreement”) is entered into as of July 25, 2014, by and between GLENN R. MATTES (the “Executive”)
and ARNO THERAPEUTICS, INC., a Delaware corporation (the “Company”).
WHEREAS, Executive
and the Company are parties to that certain Employment Agreement dated April 25, 2011 (the “Employment Agreement”),
which set forth the terms of Executive’s employment with the Company as its Chief Executive Officer and President;
WHEREAS, Executive
and the Company have determined to terminate such employment effective as of July 18, 2014 (the “Separation Date”)
and to agree to a mutually satisfactory settlement regarding Executive’s separation from the Company;
WHEREAS, Section 10
of the Employment Agreement sets forth certain compensation and other benefits payable to Executive in certain circumstances upon
the termination of his employment with the Company;
WHEREAS, paragraph
(d) of Section 10 provides that the Company’s obligation to pay to Executive the compensation and other benefits described
in Section 10 of the Employment Agreement is conditioned upon the Executive’s execution of a Release Agreement (as defined
therein); and
WHEREAS, the parties
intend that this Agreement shall constitute the Release Agreement described in Section 10(d) of the Employment Agreement.
NOW, THEREFORE, in
consideration of the foregoing, the parties hereby agree as follows:
1. Separation from Company.
Executive and Company each agree that the Employment Agreement and Executive’s employment with the Company ended effective
at the close of business on the Separation Date, and that the Company and Executive shall have no further rights or obligations
thereunder other than as explicitly set forth in this Agreement. Upon receipt by Executive of his final paycheck, which includes
payment for services through the Separation Date, Executive will have received all wages and compensation owed to him by virtue
of his employment with the Company or termination thereof, except as otherwise described in this Agreement. Executive hereby resigns
as a director of the Company and as an officer and director of all Company subsidiaries effective as of the Separation Date.
2. Separation Compensation.
In consideration for the release set forth in Section 3 below, following the Separation Date and subject to Executive’s continued
compliance with Sections 6 and 7 of the Employment Agreement, the Company agrees as follows:
| (a) | To pay to Executive a lump sum payment in the gross amount of $7,570.80 (less applicable withholding),
representing his accrued and unused vacation pay as of the Separation Date; |
| (b) | To reimburse Executive for any unreimbursed business expenses properly incurred by him prior to
the Separation Date in accordance with Company policy; |
| (c) | To pay Executive his current annualized Base Salary for a period of thirteen (13) months following
the Separation Date (representing total gross payments of $426,508.33) in regular installments in accordance with the Company's
usual payroll practices commencing with the first payroll date following the expiration of the 7-day rescission period described
in Section 4(b), below; |
| (d) | To extend until July 18, 2017, the exercise period of all stock options previously granted to Executive
pursuant to the Company’s 2005 Stock Option Plan, as amended (the “2005 Plan”) but only to the extent that such
stock options are vested and exercisable as of the Separation Date, which stock option are described on Exhibit A attached hereto
(the “Stock Options”); and |
| (e) | To allow Executive to cashlessly exercise the Stock Options, up to the extent the Stock Options
are deemed vested and exercisable as of the Separation Date (as reflected on Exhibit A) in the manner contemplated by Section 6.4(c)
of the 2005 Plan. |
In no event shall Executive be obligated
to seek other employment or take any other action by way of mitigation of the amounts payable to and benefits provided to Executive
under any provisions of this Agreement and, such amounts and benefits shall not be reduced whether or not Executive obtains other
employment.
3. Release of Claims. In
consideration for the payments and other benefits described in this Agreement, Executive hereby fully and finally releases, waives,
and discharges any and all legal claims against the Company, including Insperity, that he has through the date on which he signs
this Agreement. This full and final release, waiver, and discharge extends to legal and equitable claims of any kind or nature
whatsoever including, without limitation, the following:
(a) All claims that
Executive has now, whether or not he now knows about the claims;
(b) All claims for
attorney’s fees and costs;
(c) All claims for
alleged discrimination against his under any applicable federal, state, and local law including, without limitation, rights and
claims of age discrimination under the federal Age Discrimination in Employment Act (“ADEA”) and federal Older Workers
Benefits Protection Act (“OWBPA”); and discrimination claims under the California Fair Employment and Housing Act (“CFEHA”),
Title VII of the Civil Rights Act of 1964 (“Title VII”), and the Americans With Disabilities Act (“ADA”),
the New Jersey Law Against Discrimination, the New Jersey Family Leave Act, the New Jersey Conscientious Employee Protection Act,
the New Jersey Civil Rights Act;
(d) All claims arising
out of his employment and the termination of his employment with and service as an officer or director of the Company, including,
but not limited to, any alleged breach of contract, wrongful termination, termination in violation of public policy, defamation,
invasion of privacy, fraud, negligence, infliction of emotional distress, breach of implied contract and breach of the covenant
of good faith and fair dealing;
(e) All claims for
any other alleged unlawful employment practices arising out of or relating to his employment or separation from employment and
service as an officer or director of the Company;
(f) All claims for
any other form of pay, for example bonus pay, incentive pay, holiday pay, and sick pay; and
Provided,
however, that the foregoing does not constitute a release or waiver of Executive’s rights to (a) the payments
and benefits payable to Executive by the Company pursuant to Section 2 hereof; (b) any rights and benefits retained by or provided
to Executive pursuant to this Agreement; (c) participate in any manner in an investigation, hearing or proceeding conducted by
the Equal Employment Opportunity Commission, but Executive hereby waives any and all rights to recover under, or by virtue of,
any such investigation, hearing or proceeding; (d) exercise his rights, if any, under Section 601-608 of the Employee Retirement
Income Security Act of 1974, as amended, popularly known as COBRA and/or the New Jersey Small Employer Health Benefits Act of 1992;
(e) seek indemnification under any applicable directors & officers liability insurance policy, applicable state and federal
law, the Company’s certificate of incorporation and bylaws and pursuant to that certain Indemnification Agreement between
the Company and Executive dated April 25, 2011 (the “Indemnification Agreement”), (f) any rights under the Stock Options
(to the extent deemed vested as of the Separation Date and as modified by this Agreement), and any vested interest he may have
in any 401(k), retirement, defined benefit, defined contribution or other plan by virtue of his employment with the Company, g)
any rights or claims that may arise after this Agreement is signed, (h) any rights to any unemployment compensation benefits to
which he is entitled taking into consideration all payments he receives, (i) any rights of Executive under any other written agreement
with the Company entered into after the date of the Employment Agreement, or (j) the right to institute legal action for the purpose
of enforcing the provisions of this Agreement and/or the surviving provisions of the Employment Agreement.
Executive also hereby waives any right
to reinstatement to employment with the Company.
For purposes of this Agreement, “Executive”
includes anyone who has or obtains any legal rights or claims through Executive, and the term “Company” means Arno
Therapeutics, Inc. and each of its past and present parents, subsidiaries and other affiliated entities, if any, and each of them;
and past and present agents, officers, directors, employees, shareholders, insurers, indemnitors, attorneys, successors or assigns
of any or all of the foregoing entities. The term “Insperity” means Insperity PEO Services, L.P. (“Insperity”),
and each of its past and present parents, subsidiaries and other affiliated entities, if any, and each of them; and past and present
agents, officers, directors, employees, shareholders, insurers, indemnitors, attorneys, successors or assigns of any or all of
the foregoing entities.
4. Rights
to Counsel, Consider, and Revoke and Rescind.
(a) Executive
acknowledges that he consulted with an attorney prior to signing the Employment Agreement. The Company hereby advises
Executive to consult with an attorney prior to signing this Agreement.
(b) Executive understands that he
has the right to take up to 21 days to consider his waiver of age discrimination rights and claims under the ADEA and OWBPA, beginning
the date on which he received this Agreement. He further understands that, if he signs this Agreement, he may rescind his waiver
of age discrimination rights and claims under the ADEA and OWBPA within seven days thereafter, and his waiver will not be effective
or enforceable until this seven-day period has expired. If Executive wishes to rescind or revoke his waiver of such age discrimination
claims, he should send a notice of such rescission or revocation to the Company at 200 Route 31 North, Flemington, NJ 08822, Attn:
Lawrence Kenyon. Any exercise by Employee of his right to rescind claims under the ADEA pursuant to this Section 4 shall not entitle
him to or result in reinstatement of his employment with the Company. Employee further understands and agrees that if he rescinds
or revokes this Agreement in accordance with this Section 4, the Company shall have no obligation to provide the payments and benefits
described in Section 2, above (other than with respect to unreimbursed business expenses as described in Section 2(b)).
5. Charges.
This Agreement does not prohibit Executive from filing an administrative charge of discrimination with, or cooperating or participating
in an investigation or proceeding conducted by, the Equal Employment Opportunity Commission or other federal or state regulatory
or law enforcement agency.
6. Other
Agreements.
(a) Executive agrees that he will
surrender to the Company, no later than the date of this Agreement, all property belonging to, or purchased with the funds of,
the Company, and any equipment (including computers and cell phones), employee or security identification or access codes, pass
codes, keys, credit cards, swipe cards, client data bases, computer files, Company proposals, computer access codes, documents,
memoranda, records, files, letters, specification or other papers (including all copies and other tangible forms of the foregoing)
acquired by Executive by reason of his employment with the Company and in Executive’s possession or under his custody or
control as of the Separation Date relating to the operations, business or affairs of the Company. Executive agrees that he will
not retain any copies, duplicates, reproductions, computer disks, or excerpts thereof of Company documents. Notwithstanding anything
to the contrary contained in this Agreement, (i) Executive may remove from the Company’s premises, retain and use any third
party business cards that he accumulated during his employment with the Company, and (ii) the Company will provide to Executive
on a compact disc or other medium, and Executive may retain and use, his personal electronic contact list that he developed during
his employment with the Company on. Nothing in this Agreement shall be construed to restrict or otherwise limit the ability or
right of Executive to (x) retain and use any documents or other items relating to his employment with the Company, including documents
describing the terms of his employment or benefits or other compensation to which he has been or may in the future be entitled,
or (y) retain and use his personal belongings. The Company shall have the right to inspect all items removed from the Company’s
premises by Executive solely to ensure compliance with this Section 6(a).
(b) Executive’s obligations
under Sections 6 and 7 of the Employment Agreement shall remain in full force and effect and will survive the termination of Executive’s
employment with the Company in accordance with the terms of the Employment Agreement. Nothing in this Agreement shall be construed
to supersede or otherwise relieve Executive of such obligations. Further, the Indemnification Agreement shall survive the termination
of the Employment Agreement and Executive’s service as an officer and director of the Company in accordance with its terms,
and nothing herein shall relieve the Company and Executive of their respective rights and obligations thereunder.
(c) The Company agrees that no amendment
or modification of its certificate of incorporation or bylaws adopted after the date hereof that reduces Executive’s rights
to seek and obtain indemnification from the Company in his capacity as officer and/or director shall be effective against Executive.
(d) The Company acknowledges and
agrees that its obligations under Section 7(c) of the Employment Agreement shall remain in full force and effect and will survive
the termination of Executive’s employment with the Company in accordance with the terms of the Employment Agreement. Nothing
in this Agreement shall be construed to supersede or otherwise relieve the Company of such obligations.
(e) Executive agrees that the additional
compensation to be paid under this Agreement is due solely from Arno Therapeutics, Inc. and that Insperity has no obligation to
pay the additional compensation, even though its payment may be processed through Insperity.
(f) The Company and Executive agree
that any dispute arising out of, or relating to, this Agreement, on the breach thereof, or the interpretation thereof, shall be
exclusively decided pursuant to the provisions of Section 12(c) of the Employment Agreement which shall, for such purposes, remain
in full force and effect and will survive the termination of the Employment Agreement.
7. Miscellaneous.
This Agreement states the entire agreement between Executive and the Company with respect to the subject matter hereof and supersedes
and merges all prior negotiations, agreements, and understandings, if any. No modification, release, discharge, or waiver, of any
provision of this Agreement shall be of any force or effect unless made in writing and signed by Executive and the Company, and
specifically identified as a modification, release, or discharge, of this Agreement. If any term, clause, or provision of this
Agreement shall for any reason be adjudged invalid, unenforceable, or void, the same shall not impair or invalidate any of the
other provisions of the Agreement, all of which shall be performed in accordance with their respective terms. This Agreement shall
inure to the benefit of the successors and assigns of the Company. This Agreement shall inure to the benefit of and be enforceable
by the Executive’s legal representatives. As used in this Agreement, the “Company” shall mean the Company as
hereinbefore defined and any successor to its business and/or assets which assumes and agrees to perform this Agreement by operation
of law or otherwise.
Executive represents
that this Agreement, and the release contained in this Agreement, have been given voluntarily and free from duress or undue influence
on the part of any person or entity released by this Agreement, or by any third party. Executive acknowledges and understands that
he has no obligation to enter into this Agreement, but that the Company has no obligation to provide to Executive the payments
and benefits described under Section 10 of the Employment Agreement if he does not enter into this Agreement.
Executive has read
this Agreement carefully and understands all of its terms. he acknowledges that he has had the opportunity to discuss this Agreement
with his own attorneys prior to signing it, and to make certain that he understands the meaning of the terms and conditions contained
in this Agreement and fully understands the content and effect of this Agreement. In agreeing to sign this Agreement, Executive
acknowledges that he has not relied on any representations or statements, whether oral or written, other than the express statements
of this Agreement.
IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the date(s) set forth below.
EXECUTIVE: |
ARNO THERAPEUTICS, INC. |
|
|
/s/ Glenn R. Mattes
Glenn R. Mattes
Dated: July 25, 2014 |
By: /s/ Lawrence A. Kenyon
Name: Lawrence A. Kenyon
Its: COO and CFO
Dated: July 25, 2014 |
EXHIBIT A
Original Grant Date |
|
Shares Subject to Original Grant |
|
Ex. Price |
|
Shares Deemed Vested and Exercisable at Separation Date |
4/25/2011 |
|
176,578 |
|
$ 2.40 |
|
176,578 |
4/25/2011 |
|
117,719 |
|
$ 2.40 |
|
117,719 |
1/14/2013 |
|
38,700 |
|
$ 2.40 |
|
33,325 |
1/14/2013 |
|
25,800 |
|
$ 2.40 |
|
8,600 |
11/4/2013 |
|
386,697 |
|
$ 2.40 |
|
96,674 |
1/24/2014 |
|
408,892 |
|
$ 2.90 |
|
0 |
|
|
|
|
TOTAL |
|
432,896 |
Note: All share and prices have been
adjusted for the 1:8 reverse split of the Company’s common stock effected on Oct. 29, 2013.
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024